Subcutaneous daratumumab

Benefits of switching from intravenous to subcutaneous daratumumab

Daratumumab is a CD38-directed monoclonal antibody indicated to treat multiple myeloma (MM). Daratumumab was initially administered intravenously (IV), ...

a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Subcutaneous daratumumab is thought to be easier to administer and to cause fewer administration-related reactions. In this study (COLUMBA), we ...

Subcutaneous daratumumab and hyaluronidase-fihj in newly ...

Daratumumab, a human immunoglobulin G1 kappa monoclonal antibody that targets CD38, is currently approved as monotherapy and in varying combinations with ...

Official Consumer Website | DARZALEX® & DARZALEX FASPRO ...

Be heard in the face of a multiple myeloma diagnosis or a relapse. · What is DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)? · Important Safety Information.

DARZALEX® (daratumumab)-SC based quadruplet regimen ...

Daratumumab is the only CD38-directed antibody approved to be given subcutaneously to treat patients with multiple myeloma.2 Daratumumab SC is ...

Daratumumab and hyaluronidase-fihj (subcutaneous route)

Daratumumab and hyaluronidase-fihj combination injection is used together with bortezomib, melphalan, and prednisone to treat newly diagnosed multiple myeloma.

FDA Approves Subcutaneous Daratumumab Plus VRd in Multiple ...

The FDA approved Darzalex Faspro plus VRd for induction and consolidation in select patients with newly diagnosed multiple myeloma.

4084-Multiple myeloma daratumumab subcutaneous - eviQ

This protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted ...

daratumumab (subcut) | Cancer Care Ontario

The incidences below were mostly reported for daratumumab IV. Adverse events associated with the subcutaneous formulation are denoted with “^”. ORGAN SITE. SIDE ...

Daratumumab Plus Standard Therapy for Multiple Myeloma - NCI

In the PERSEUS trial, the researchers used subcutaneous daratumumab. The PERSEUS trial. More than 700 people with newly diagnosed multiple ...

Eliminating the monitoring period with subcutaneous daratumumab

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience. Kathryn T. Maples.

Subcutaneous Versus IV Daratumumab May Be a Preferred ...

Subcutaneous daratumumab could be considered a “preferred” treatment choice for appropriate patients with R/R MM.

FDA, EMA Receive Applications for Subcutaneous Daratumumab in ...

Applications have been submitted to the FDA and EMA seeking approval for daratumumab in high-risk smoldering multiple myeloma.

Subcutaneous Daratumumab for Multiple Myeloma: Applying the ...

This publication provides a clinical review of SC daratumumab, including indications and appropriate use, pivotal clinical trial data, management of adverse ...

DARZALEX® SC - Medsafe

Bortezomib is administered by subcutaneous (SC) injection or intravenous (IV) injection at a dose of 1.3 mg/m2 body surface area twice weekly ...

Evaluation of administration-related reactions with subcutaneous ...

Daratumumab-hyaluronidase-fihj (Dara-SQ), used in the treatment of plasma cell disorders, is associated with improved outcomes.

Subcutaneous daratumumab in patients with relapsed or refractory ...

DARA SC 1800 mg was well tolerated in relapsed/refractory multiple myeloma, with a low infusion-related reaction rate and reduced administration time.

Clinical Administration Characteristics of Subcutaneous and ...

Daratumumab (DARA) is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action. DARA is ...

Subcutaneous daratumumab plus pomalidomide and ... - The Lancet

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma ( ...

Administration - Darzalex

DARZALEX FASPRO ® is for subcutaneous use only. ... Pre-medicate patients 1 to 3 hours before each dose with a histamine-1 receptor antagonist, acetaminophen, and ...